Approval Replaces a Case-by-Case Access Route
The Food and Drug Administration has approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, making a drug that patients could previously obtain only through clinical trials or a compassionate use program available for prescribing by treating oncologists.
The approval notice from the agency's Center for Drug Evaluation and Research covers patients who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy. The drug, developed by Revolution Medicines, inhibits the RAS family of GTPases.
That second group matters more than it may appear. Multiagent regimens for pancreatic cancer are demanding, and a substantial share of patients are too frail, too old, or carry too many other conditions to tolerate them. Until now, those patients often had no active treatment option at all. The label now includes them without requiring them to fail a regimen first.
MedicalDaily previously reported on who qualified for expanded access to daraxonrasib while the drug was still investigational. Under that program, availability depended on whether an individual cancer center had opened the protocol, which happened institution by institution rather than nationwide. That bottleneck is now gone.
The Label Defines Who Qualifies
Approval rested on RASolute 302, a randomized, open-label, multicenter trial in which 500 patients whose disease had progressed after one prior line of systemic therapy were assigned in equal numbers to daraxonrasib or to a physician's choice of standard chemotherapy.
The FDA found that the trial produced statistically significant improvements in overall survival, progression-free survival, and tumor response rate compared with chemotherapy, both among patients carrying a RAS G12 mutation and in the overall population. Survival and progression outcomes were assessed by reviewers blinded to which treatment each patient received.
In the overall population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, with a hazard ratio of 0.40. Median progression-free survival was 7.2 months against 3.6 months, with a hazard ratio of 0.49. Thirty percent of patients on daraxonrasib had a measurable tumor response, compared with 11 percent on chemotherapy. Trial details are posted on ClinicalTrials.gov.
The dose is 300 milligrams taken orally once daily, continued until the disease progresses or side effects become unacceptable. That an advanced pancreatic cancer therapy is taken by mouth rather than infused is itself a practical difference for patients weighing time in a treatment chair against time at home.
Full prescribing information is posted through the agency's Drugs@FDA database.
Molecular Testing Becomes the Gating Step
For families, the most useful action item is not the drug name. This confirms that the tumor has been molecularly profiled and that the results are in the chart.
RAS mutations are present in the large majority of pancreatic cancers, and the trial showed a benefit in the overall population as well as in the RAS G12 subgroup. But treatment decisions still run through a tumor's molecular profile, and not every patient has had comprehensive testing, particularly if their diagnosis came at a community practice rather than an academic cancer center. Asking the oncologist whether molecular testing was done, when, and what it showed is a reasonable question at any point in treatment.
Patients who are already receiving daraxonrasib through expanded access should ask their care team how the approval affects their supply and billing, since compassionate use programs typically provide the drug at no charge while approved drugs transition to insurance coverage.
Anyone currently on chemotherapy should not stop or change treatment on the basis of this news. Whether to switch, and when, depends on how a specific cancer is behaving and what a patient can tolerate. That conversation belongs with a treating oncologist.
Coverage, Side Effects and Open Questions
The prescribing information carries warnings and precautions for skin and soft tissue toxicity, mouth sores and other oral problems, diarrhea, tears in the wall of the stomach or intestines, lung inflammation, and harm to a developing fetus. Several of these, particularly the skin and mouth effects, are the kind that erode quality of life and cause patients to miss doses, which makes early reporting to the care team important rather than something to endure quietly.
Revolution Medicines has not published a list price, and no insurer coverage policies have been announced. Oral cancer drugs are usually processed under a plan's pharmacy benefit, which often means prior authorization and specialty pharmacy dispensing. Patients should ask the prescribing office who handles authorization and whether the manufacturer runs a patient assistance program, and should expect the first fill to take longer than a routine prescription.
Several things remain unknown. The trial enrolled patients who had already received one line of therapy, so the results do not establish how the drug performs as an initial treatment. Longer-term survival beyond the trial follow-up period has not yet been established, and the upper bound of the confidence interval for the 13.2-month survival estimate could not be estimated from the available data.
The review was conducted under Project Orbis in collaboration with Health Canada, with European and Japanese regulators serving as official observers, so decisions in those regions may follow. The application also moved through the agency's Real-Time Oncology Review pilot and the Commissioner's National Priority Voucher program, and the drug had already received breakthrough therapy and orphan drug designations. The FDA said the approval came about six and a half months ahead of its goal date. MedicalDaily will report when pricing, coverage policies, or additional trial results become available.
Key Questions Answered
What changed? The FDA approved daraxonrasib for metastatic pancreatic adenocarcinoma. It was previously available only through clinical trials or an expanded access protocol that individual cancer centers had to open.
Who is eligible under the label? Adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy.
What did the trial show? In RASolute 302, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy, with improvements in progression-free survival and tumor response.
How is it taken? As 300 milligrams by mouth once daily, continued until the disease progresses or side effects become unacceptable.
What are the main warnings? Skin and soft tissue toxicity, mouth sores, diarrhea, tears in the stomach or intestinal wall, lung inflammation, and fetal harm.
Does everyone with pancreatic cancer qualify? No. The approval is specific to metastatic adenocarcinoma meeting the label criteria. Molecular testing and a treating oncologist's assessment determine whether it fits an individual case.
Is it known to be effective as a first-line treatment? Not from this trial. RASolute 302 enrolled patients who had already received one prior line of therapy.
